Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models
- 1.6k Downloads
Imaging of beta cell mass (BCM) is a major challenge in diabetes research. The vesicular monoamine transporter 2 (VMAT2) is abundantly expressed in human beta cells. Radiolabelled analogues of tetrabenazine (TBZ; a low-molecular-weight, cell-permeant VMAT2-selective ligand) have been employed for pancreatic islet imaging in humans. Since reports on TBZ-based VMAT2 imaging in rodent pancreas have been fraught with confusion, we compared VMAT2 gene expression patterns in the mouse, rat, pig and human pancreas, to identify appropriate animal models with which to further validate and optimise TBZ imaging in humans.
We used a panel of highly sensitive VMAT2 antibodies developed against equivalently antigenic regions of the transporter from each species in combination with immunostaining for insulin and species-specific in situ hybridisation probes. Individual pancreatic islets were obtained by laser-capture microdissection and subjected to analysis of mRNA expression of VMAT2.
The VMAT2 protein was not expressed in beta cells in the adult pancreas of common mouse or rat laboratory strains, in contrast to its expression in beta cells (but not other pancreatic endocrine cell types) in the pancreas of pigs and humans. VMAT2- and tyrosine hydroxylase co-positive (catecholaminergic) innervation was less abundant in humans than in rodents. VMAT2-positive mast cells were identified in the pancreas of all species.
Primates and pigs are suitable models for TBZ imaging of beta cells. Rodents, because of a complete lack of VMAT2 expression in the endocrine pancreas, are a ‘null’ model for assessing interference with BCM measurements by VMAT2-positive mast cells and sympathetic innervation in the pancreas.
KeywordsBeta cell mass Imaging Pancreas Tetrabenazine Vesicular monoamine transporter
GenBank accession number
Beta cell mass
Positron emission tomography
Sodium citrate, sodium chloride buffer
Vesicular monoamine transporter
We and others have previously identified the catecholamine transporters VMAT1 and VMAT2 (vesicular monoamine transporter 1 and 2) and characterised their expression patterns in rodents [1, 2] and in primates . VMAT2 is the only vesicular monoamine transporter produced in the brain and in postganglionic sympathetic neurons in all species examined . VMAT1 is likewise invariably expressed in the adrenal medulla and small intensely fluorescent cells in mammals; however, there is pronounced mammalian species variation in the expression of VMAT2 in endocrine tissues . Thus, while VMAT1 is the major vesicular catecholamine transporter in the adrenal medulla of rodent species, VMAT1 and VMAT2 are co-expressed in chromaffin cells in primate species [5, 6] and VMAT2 is predominantly expressed in the bovine adrenal medulla [7, 8]. VMAT1 and VMAT2 are both transporters for serotonin, dopamine, noradrenaline (norepinephrine) and adrenaline (epinephrine), and the function of both is blocked by reserpine, while VMAT2 also transports histamine and binds tetrabenazine (TBZ) . The different properties of VMAT1 and VMAT2 are exhibited in enterochromaffin cells of the gut, which express VMAT1 and accumulate serotonin but not histamine, and enterochromaffin-like cells of the oxyntic mucosa of the stomach, which produce VMAT2 and accumulate histamine .
Although the beta cell is not known to synthesise, store and release biogenic amines, we previously demonstrated that VMAT2 is produced in most, if not all, human and non-human primate beta cells [5, 10], and this finding has been copiously confirmed [11, 12]. Therefore, VMAT2 is a putative molecular target for the quantitative imaging of pancreatic beta cell mass (BCM) in diabetic patients [13, 14, 15, 16]. Although VMAT2 is expressed within the cell, rather than on the cell surface, it can be labelled in vivo with the lipophilic positron emission tomography (PET) ligand [11C]dihydrotetrabenazine (DTBZ). Several groups have used [11C]DTBZ to estimate the density of VMAT2-positive nerve terminals in the human brain in neurodegenerative disorders such as Parkinson’s disease [17, 18], and the dynamics of VMAT2 occupancy by catecholamines in methamphetamine users has also been probed using labelled DTBZ . More recently, [11C]DTBZ has been employed for PET analysis of BCM in humans. However, animal models have been deemed critical for optimising the chemistry and pharmacodynamics of DTBZ analogues, to accelerate their widespread acceptance in clinical practice, as markers that might be used even more widely for imaging of BCM in human patients at critical milestones in the progression of a disease, such as its diagnosis, determination of its prognosis and assessment of therapy.
Rats, mice and pigs have all been used as models for DTBZ imaging of beta cells but the interpretation of the results of rodent DTBZ imaging in the pancreas has been controversial [20, 21, 22, 23, 24, 25, 26, 27, 28, 29]. This is partly because the biochemical, histochemical and molecular biological characterisation of VMAT2 expression in the pancreas in these species, compared with humans, has yet to be rigorously examined. Therefore, we investigated here the extent to which VMAT2 is expressed in beta cells of rodents in comparison with humans to qualify rodents as suitable animal models for in vivo BCM imaging with TBZ-based PET tracers. In addition, we evaluated the abundance of VMAT2 in pancreatic cellular compartments other than beta cells, including pancreatic nerves and mast cells, as being a possible contributor to PET signals obtained with TBZ tracer. Finally, we examined VMAT2 expression in other species that are commonly used as animal models in preclinical studies.
Animals and tissue samples
Pancreatic tissues from adult male mice (C57/bl6, BALB/c, C3H/HeN) and rats (Wistar, Sprague–Dawley, Lewis) of various strains (Charles River, Sulzfeld, Germany) were rapidly collected in accordance with the German Law for animal protection. Immediately after the rodents were killed by exposure to isoflurane, tissue samples were collected and were frozen in liquid nitrogen (for RNA extraction) or isopentane (for preparing cryosections) or were immersed overnight in Bouin Hollande fixative or freshly prepared paraformaldehyde (for immunocytochemical processing). Human pancreatic tissue sections were prepared as described previously . Four frozen normal human pancreas specimens, containing non-pathological endocrine islets, were provided by the Biomaterial Bank of the University Cancer Center of Düsseldorf, Germany. The tissue was taken from patients (aged 47–71 years) suffering from pancreatic adenocarcinoma in approval with the local ethics committee. Porcine adrenal and pancreatic tissues were collected immediately post-mortem from adult pigs in the local slaughter house. In addition tissues from slaughtered 3-month-old female domestic pigs (Sus scrofa domestica; Lehr- und Forschungsstation Oberer Hardthof, Justus Liebig University, Giessen, Germany) were provided by T. Steinfeldt (Department of Anaesthesiology and Critical Care, University Hospital Giessen-Marburg, Philipps University Marburg) in accordance with the Principles of Laboratory Care. Tissues were cut into small blocks with a side length of less than 10 mm and processed as described above.
Using the P.A.L.M. Microbeam system (Carl Zeiss, Munich, Germany), laser-capture microdissection (LCM) was performed on frozen counterstained sections of mouse and pig pancreas and adrenal glands. LCM of human pancreas was carried out under fluorescent illumination (488 nm excitation wavelength) taking advantage of the autofluorescent properties of human beta cells . The detailed procedures are described in electronic supplementary material (ESM) Methods.
Total RNA from tissues was isolated using TRIzol Reagent (Invitrogen, Darmstadt, Germany). Isolation of total RNA from microdissected islets was performed with a micro-scale RNA isolation kit (RNAqueous-Micro; Ambion, Austin, Texas). All RNA samples were treated with RNase-free DNase I (Roche Diagnostics, Mannheim, Germany) at 37°C for 30 min. RNA quality was measured by capillary gel electrophoresis (Experion Bioanalyzer; BioRad Medical Diagnostics GmbH, Dreieich, Germany). Details are described in ESM Methods. Synthesis of cDNA and PCR was performed as described previously . All cDNA was tested for genomic DNA contamination by omitting reverse transcriptase in the synthesis reaction. Gene- and species-specific primer pairs are listed in ESM Table 1. Identity of all PCR products were confirmed by double-stranded DNA sequencing (SEQlab, Göttingen, Germany). A standard PCR protocol was used with an annealing temperature of 60°C. After 30–35 cycles 10 μl of each PCR reaction (LCM samples, 40 cycles) were loaded and electrophoresed on 1.5% agarose gels containing ethidium bromide and visualised by ultraviolet transillumination (BioRad, Munich, Germany).
Cloning of porcine VMAT2
VMAT2 (also known as SLC18A2) cDNA was cloned from the adrenal medulla of Sus scrofa domestica using a PCR cloning strategy. Two porcine expressed sequence tags (ESTs) were identified in GenBank with 87% homology to the 5′ end (GenBank accession No. [Acc.Nr.] CN158265.1) and 92% homology to the 3′ end (Acc.Nr. CN160191.1) of human VMAT2 (Acc.Nr. NM_003054.4) and used for primer design. After reverse transcription of high-quality porcine adrenal RNA (RNA quality index [RQI] >9) with Superscript III (Invitrogen), PCR was performed with PfuUltra High Fidelity DNA Polymerase (Agilent Technologies, Waldbronn, Germany) using the following primer pair: forward CAGGGCAGGCAGCCGCAGG; reverse TCACTTTCACCAGGGATGAGCGG. Sequence identities of amplicons from three independent PCR reactions were determined by custom double-stranded DNA sequencing (Seqlab, Göttingen, Germany). A cDNA (1,701 bp) containing the full-length coding sequence of porcine VMAT2 mRNA was obtained (Acc.Nr. KC552360), which was 100% identical to the VMAT2 mRNA sequence predicted by computational analysis (Acc.Nr. XM_001927394.3). The deduced sequence codes for the 517-amino-acid-long protein, which shares 93% homology to human VMAT2, are shown in ESM Fig. 1.
Generation of DNA templates for in situ hybridisation probes
Species-specific DNA templates for VMAT2 were generated as follows. A 734-bp-long mouse-specific Vmat2 cDNA (nucleotides [nt.]1076–1809; Acc.Nr. NM_17253) was obtained (Acc.Nr. NM_17253) by RT-PCR from brain cDNA extracts. A 368-bp-long BamHI/XbaI cDNA fragment of rat Vmat2 (nt. 233–500; Acc.Nr. L00603.1) was subcloned into pCRII . A full-length human VMAT2 cDNA (Acc.Nr. L23205) was used as PCR template to generate two cDNA probes directed against the 5′ end (nt. 113–878) and the 3′ end (nt. 9,070–1,769), respectively. Similarly, the cloned pig VMAT2 cDNA served as template to produce a 727-bp-long 5′-specific and a 731-bp-long 3′-specific fragment. For detection of mRNA for the genes encoding insulin and glucagon in the mouse, a 630-bp-long cDNA (nt. 332–661, Acc.Nr. NM_00838.6) and a 545-bp-long cDNA (nt. 155–699, Acc.Nr. NM_008100.3), respectively, were generated by RT-PCR cloning from mouse pancreas. All DNA fragments were sublconed into pGEM-T (Promega, Mannheim, Germany), if not otherwise stated, for in vitro transcription to synthesise RNA probes in anti-sense- and sense-strand orientation using the appropriate RNA polymerases SP6 and T7 as described .
In situ hybridisation
Frozen sections of pancreas (10 μm thick) from all species examined were cut on a LEICA cryostat, thaw-mounted on adhesive slides and subjected to the hybridisation procedure as described . Sections were covered with 50 μl hybridisation buffer containing [35S]UTP-labelled riboprobes (5 × 104 dpm/μl), coverslipped and incubated for 14 h at 60°C in a humid chamber. Slides were washed in decreasing concentrations of 2× SSC, RNase A-treated, dehydrated, air dried and then coated with NTB-2 nuclear emulsion (Eastman Kodak, Rochester, NY, USA). After exposure times between 4 and 28 days, slides were developed. Sections were analysed with the Olympus AX70 fluorescence microscope (Olympus Optical, Hamburg, Germany) and results were documented with a digital photographic camera system (Diagnostics Instruments, Ann Arbor, MI, USA).
Animals were perfused with PBS and Bouin Hollande or freshly prepared 4% paraformaldehyde fixative. All antisera used had been characterised previously [10, 34] (ESM Table 2). Species-specific biotinylated secondary antibodies (1:200 working dilution; Dianova, Hamburg, Germany) were employed using the Vectastain ABC method (Vectastain Elite ABC Kit; Vector Laboratories, Burlingame, CA, USA), including ammonium nickel sulfate-enhanced 3,3-diaminobenzidine (Sigma, Deisenhofen, Germany) reactions to enhance antibody visualisation.
Immunofluorescence and morphometric analysis
After deparaffinisation and blocking procedures appropriate combinations of two primary antibodies raised in different donor species were co-applied in PBS/1% BSA and incubated overnight at 4°C, followed by incubation for 2 h at 37°C. After extensive washing in distilled water followed by PBS, immunoreactions for the first primary antibody were visualised with species-specific secondary antibodies labelled with Alexa Fluor 647 (MoBiTec, Göttingen, Germany), diluted 1:200 in 1% BSA/PBS. The second primary antibody was visualised by a two-step procedure including species-specific biotinylated secondary antisera (Dianova), diluted 1:200 in 1% BSA/PBS followed by streptavidin conjugated with Alexa Fluor 488, diluted 1:100 in 1% BSA/PBS. Incubation times were 45 min with biotinylated secondary antibodies, followed by a 2 h incubation with a mixture of fluorochrome-conjugated secondary antibody and streptavidin. Biotinylated secondary antiserum incubations with the species-specific VMAT2 antibodies were followed by tyramide signal amplification using the individual indirect tyramide reagent pack (catalogue No. SAT700; PerkinElmer, Rodgau, Germany) and visualisation with streptavidin conjugated with Alexa Fluor 488 (dilution 1:200; MoBiTec, Göttingen, Germany). A directly labelled secondary antibody with Alexa Fluor 647 was applied simultaneously to the other primary antibody species for 2 h at 37°C.
Immunofluorescent signals were documented as digitised false colour images (8-bit tiff format) with an Olympus BX50WI confocal laser scanning microscope (Olympus Optical, Hamburg, Germany) and Olympus Fluoview 2.1 software.
For morphometric analysis, serial sections (n = 9) from four different levels of human pancreas containing islets were stained with VMAT2 and tryptase. Pictures were taken with a ×10 objective and analysed using Image J software (National Institutes of Health, Bethesda, MD, USA).
Vmat2 in situ hybridisation of rodent pancreas
Absence of Vmat2 mRNA in laser-microdissected mouse pancreatic islets
Confocal analysis of VMAT2 immunoreactive structures in rodent pancreas
VMAT2 mRNA expression in pig and human pancreas
VMAT2 mRNA in microdissected islet cells from pig and human pancreas
Co-localisation of VMAT2 in beta cells of pig and human pancreas
Identification of VMAT2 in mast cells and in sympathetic innervation in human pancreas
The abundance of VMAT2 in pancreatic beta cells is remarkably species dependent. On the basis of the results reported here, we conclude that VMAT2 mRNA and VMAT2 protein is absent from beta cells of adult male rodent pancreatic islets but is present in pig and human beta cells. The relatively high abundance of pancreatic VMAT2 innervation in rodents (Fig. 3) as compared with humans (Figs 6, 8) suggests that any specific pancreatic binding obtained with DTBZ-based PET tracers in rat or mouse is most likely related to VMAT2 in sympathetic nerves and mast cells present in both species. This may account for the lack of decrease in the small signal obtained even after treatment with streptozotocin, which results in beta cell loss in the rat pancreas . Indeed, the presence of VMAT2 in sympathetic nerves and mast cells throughout the pancreas, and species differences with regard to sympathetic innervation of the endocrine pancreas, must be taken into account in attempts to quantify BCM with DTBZ-based PET tracers in any species.
Rodents may be useful as animal models for pancreatic imaging with DTBZ PET tracers but only insofar as they provide controls for background and interfering signals other than VMAT2 presence in the pancreatic islets themselves. Importantly, the failure to adequately estimate BCM using DTBZ imaging in rodents does not reflect the lack of suitability of this ligand for imaging BCM in human patients, as some have suggested , but rather simply that the rodent is not the correct model for addressing this issue.
In humans we have shown that the relationship between the proportional areas of VMAT2-immunopositive beta cells and mast cells is about 9:1 implying that mast cells may confound estimation of BCM with DTBZ ligands only to a minor extent, if at all. However, as the PET signal reflects VMAT2 binding density, rather than area, the precise quantitative contribution of VMAT2 protein per mast cell and beta cell to which DTBZ ligands can bind in vivo remains to be shown. This information is obtainable only by imaging, modelled in transgenic rodents, or determined by quantitative topological analysis of in vivo DTBZ imaging itself.
So far, it appears that VMAT2 abundance in endocrine tissues is uniformly high or low depending on the species. Thus rodents produce little VMAT2 in the adrenal medulla and no VMAT2 in the endocrine pancreas, while primate VMAT2 abundance is relatively high in both the adrenal medulla and the endocrine pancreas. Consistent with these observations, we found VMAT2, by immunohistochemistry and by RT-PCR following LCM, to be present in both the adrenal medulla and the pancreatic islets of the pig.
Detailed examination reveals that, as in humans, VMAT2 presence in pig islets is confined to insulin-expressing beta cells. Importantly, neither glucagon-containing alpha cells nor somatostatin-containing delta cells in the endocrine pancreas of humans or pigs contain VMAT2, confirming the findings of our previous investigations in humans and non-human primates . In contrast to a previous report , we only rarely observed VMAT2 expression in PP cells derived from human or pig pancreas. Given the small fraction of PP compared with insulin cells in the endocrine pancreas, and the relatively high and uniform VMAT2 level in the latter, it appears that this does not represent a major confounder in the estimation of human BCM using VMAT2 ligands.
In summary our findings indicate that the pancreatic islets of mice and rats do not contain VMAT2, except in the sympathetic nerve terminals that innervate the islets. An additional interesting possibility for examination of DTBZ binding using rodent models, however, is the development of transgenic expression of human VMAT2 in the mouse pancreas as a convenient imaging and biological model for studying the effect of VMAT2 level on beta cell function in humans. Porcine pancreas, like that of humans, contains VMAT2 in beta cells. Therefore the pig is a potential model, without transgenic manipulation, for estimation of BCM using TBZ analogues and has the further advantage of being frequently employed as an animal model in the study of cardiovascular and endocrine function in heart and metabolic disease states. Non-human primates are suitable models for DTBZ imaging of beta cells and, indeed, have been used by several laboratories for PET imaging of vesicular and plasma membrane biogenic amine transporters [35, 36]. Rodents, due to an absence of VMAT2 in islet cells, represent an interesting and possibly critical ‘null’ model for establishing a background for DTBZ imaging in the pancreas and for assessment of interference with BCM measurements by VMAT2-positive nerve terminals and mast cells. Development of Vmat2-transgenic rodent models for further analysis of DTBZ imaging of BCM could also be considered in a translational context. Finally, mammalian species specificity of VMAT2 production in beta cells is a timely and potent reminder that translational research in the development of biomarkers for human disease depends on the full and rigorous determination of the precise chemical anatomy of imaging targets not only in humans but in the species in which translation research leading to clinical development is carried forward.
We are grateful to B. Wiegand, M. Schneider, H. Hlawaty and M. Zibuschka (Department of Molecular Neuroscience, Institute of Anatomy and Cell Biology, University of Marburg) for providing expert technical support and also to T. Steinfeldt (Department of Anaesthesiology and Critical Care, University Hospital Giessen-Marburg, Philipps University Marburg) for collecting porcine tissue.
Support by the BetaImage Consortium and EU grant EU FP7/-2013 No. 222980, and the University of Marburg Medical Faculty is gratefully acknowledged. L. E. Eiden acknowledges the NIMH Intramural Research program (under Project 1Z01MH002386) for research support.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
MKHS, LEE and EW were responsible for the conception of the study, analysed and interpreted the data and wrote the manuscript. NRH, NK, MK and MA made substantial contributions to acquisition and interpretation of data and revised the manuscript. All authors approved the final version of the manuscript.